- Home
- HROW vs NVAX Comparison
HROW vs NVAX Comparison
Compare HROW & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HROW
- NVAX
- Stock Information
- Founded
- HROW 1998
- NVAX 1987
- Country
- HROW United States
- NVAX United States
- Employees
- HROW N/A
- NVAX N/A
- Industry
- HROW Biotechnology: Pharmaceutical Preparations
- NVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HROW Health Care
- NVAX Health Care
- Exchange
- HROW Nasdaq
- NVAX Nasdaq
- Market Cap
- HROW 1.3B
- NVAX 1.3B
- IPO Year
- HROW N/A
- NVAX 1995
- Fundamental
- Price
- HROW $28.95
- NVAX $7.99
- Analyst Decision
- HROW Strong Buy
- NVAX Buy
- Analyst Count
- HROW 5
- NVAX 6
- Target Price
- HROW $55.40
- NVAX $17.83
- AVG Volume (30 Days)
- HROW 348.0K
- NVAX 3.7M
- Earning Date
- HROW 03-18-2025
- NVAX 02-27-2025
- Dividend Yield
- HROW N/A
- NVAX N/A
- EPS Growth
- HROW N/A
- NVAX N/A
- EPS
- HROW N/A
- NVAX N/A
- Revenue
- HROW $169,138,000.00
- NVAX $885,193,000.00
- Revenue This Year
- HROW $49.66
- NVAX N/A
- Revenue Next Year
- HROW $47.62
- NVAX N/A
- P/E Ratio
- HROW N/A
- NVAX N/A
- Revenue Growth
- HROW 48.15
- NVAX N/A
- 52 Week Low
- HROW $9.30
- NVAX $3.81
- 52 Week High
- HROW $59.23
- NVAX $23.86
- Technical
- Relative Strength Index (RSI)
- HROW 36.01
- NVAX 42.04
- Support Level
- HROW $29.63
- NVAX $7.70
- Resistance Level
- HROW $32.50
- NVAX $8.54
- Average True Range (ATR)
- HROW 1.64
- NVAX 0.39
- MACD
- HROW 0.01
- NVAX -0.04
- Stochastic Oscillator
- HROW 15.72
- NVAX 23.58
About HROW Harrow Inc.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans.
About NVAX Novavax Inc.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe.